An idiopathic inflammatory myopathy of childhood resulting in muscle weakness.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding juvenile polymyositis is limited due to its rarity and the lack of systematic clinical studies. Conditions like JPM, which affect fewer than 200,000 individuals in the United States, often struggle to attract the necessary research funding and attention. Additionally, the variability in clinical presentation makes it difficult to establish a comprehensive understanding of the disease.
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Currently, there are several orphan drugs in development for juvenile polymyositis, including (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate and Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein. There are also 20 active clinical trials exploring various aspects of juvenile polymyositis. More information can be found at ClinicalTrials.gov by searching for juvenile polymyositis.
Actionable guidance for navigating care for juvenile polymyositis
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding juvenile polymyositis is limited due to its rarity and the lack of systematic clinical studies. Conditions like JPM, which affect fewer than 200,000 individuals in the United States, often struggle to attract the necessary research funding and attention. Additionally, the variability in clinical presentation makes it difficult to establish a comprehensive understanding of the disease.
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Currently, there are several orphan drugs in development for juvenile polymyositis, including (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate and Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein. There are also 20 active clinical trials exploring various aspects of juvenile polymyositis. More information can be found at ClinicalTrials.gov by searching for juvenile polymyositis.
Actionable guidance for navigating care for juvenile polymyositis
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding juvenile polymyositis is limited due to its rarity and the lack of systematic clinical studies. Conditions like JPM, which affect fewer than 200,000 individuals in the United States, often struggle to attract the necessary research funding and attention. Additionally, the variability in clinical presentation makes it difficult to establish a comprehensive understanding of the disease.
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Currently, there are several orphan drugs in development for juvenile polymyositis, including (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate and Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein. There are also 20 active clinical trials exploring various aspects of juvenile polymyositis. More information can be found at ClinicalTrials.gov by searching for juvenile polymyositis.
Actionable guidance for navigating care for juvenile polymyositis
To navigate juvenile polymyositis, consider seeking a pediatric rheumatologist or a neurologist with expertise in inflammatory myopathies. These specialists can provide tailored care and management strategies. You may also explore opportunities to participate in clinical trials, which can be found at ClinicalTrials.gov. For additional resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov, which may offer insights into ongoing research and potential support options.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning juvenile polymyositis
Updated Jan 28, 2026
The MIHRA initiative focuses on gathering patient-rooted insights to shape research in myositis and related conditions. Sponsored by multiple organizations, including Myositis International and The Myositis Association, this project emphasizes qualitative investigations to better understand patient experiences.